Congratulations to David Weiss, PhD, co-PI of the Heteroresistance AST team, currently participating in the Biolocity Launch program. David Weiss, is the director of Emory’s Antibiotic Resistance Center and his team received a five-year $11 million grant from NIAID to continue their work in studying heteroresistance to treat bacterial infections.
Recent News
Sanguina Announces Collaboration with AstraZeneca
Congratulations to Biolocity graduate company, Sanquina, on their newly announced collaboration with AstraZeneca on a study to develop a custom version of AnemoCheck Mobile, a smartphone application that provides noninvasive and equipment-free hemoglobin levels for patients with anemia of chronic kidney disease. Learn more about the collaboration here.
The AnemoCheck/Sanguina Team, Dr. Wilbur Lam and Erika Tyburski, received support from the Biolocity program (then the Coulter Translational Program) in 2016. We are excited for their continued success and this new collaboration with AstraZeneca!
“Biolocity enabled us to receive an FDA 510(k) clearance on our first generation product. We couldn’t have done it without the support of Biolocity.”
– Erika Tyburski, AnemoCheck
Brown Family Innovation Gift
The Biolocity team is grateful for the generosity of John & Rosemary Brown in supporting our work to accelerate innovation. Their gift will help expand our support of entrepreneurs at Emory and Georgia Tech who are developing early-stage biomedical technologies that positively impact patient health.
Guide Therapeutics Acquisition
The Biolocity team is pleased to share that graduate company, Guide Therapeutics, a developer of nonviral drug delivery vehicles for genetic medicines, was acquired by Beam Therapeutics in February of 2021. Details on their merger are available here.
Guide Therapeutics Principle Investigator, Dr. James Dahlman, participated in the Biolocity Launch program in 2019 receiving project management and business mentorship to assist in completing commercialization milestones for his GuideTX technology. We are thrilled about his recent success and company acquisition!
“As a scientist without formal business training, I had no idea how to speak with Venture Capitalists or create an appropriate pitch deck. The Biolocity team helped me learn these valuable skills.”
– James Dahlman, PhD Assistant Professor, Department of Biomedical Engineering, Georgia Institute of Technology & Emory School of Medicine
Biolocity Awarded EDA Capital Challenge Grant
Biolocity is proud to be named a 2020 Capital Challenge Grant recipient. This award from the U.S. Economic Development Administration (EDA) provides us with the opportunity to launch a new, early-stage life science fund that can bridge the critical gap in technology development from bench to scalable business. We aim to help entrepreneurs build successful businesses and create sustainable jobs in the region by funding technology-driven start-ups in the life sciences.